ArticleFrontiers in medicine2022

A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19.

Adeola Fowotade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.